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Introduction
Down syndrome (DS) is one of the most common 
genetic disorders caused by the presence of 3 copies of 
chromosome 21 (Hsa21) instead of the usual two, which 
occurs during the meiotic cellular division phase.1
The worldwide prevalence of DS is 14 per 10 000 live 
birth. However, this prevalence is different, based on 
socioeconomic factors.2,3 Three different types of DS 
consist of trisomy 21 or non-disjunction (most common), 
Robertsonian translocation, and mosaicism.4
DS impair normal brain development, cause a small 
cerebellum, frontal, and temporal cortex, as well as 
simplified appearances of sulci and a narrow superior 
temporal gyrus.5 High-resolution MRI in subjects with DS 
demonstrates lower volume in different brain structures 
such as the cerebellum, cingulate gyrus, frontal cortex, 
superior temporal cortex, and hippocampus, compared to 
the normal population.6
 These changes could be the main reason for various 
range of intellectual abnormalities, including cognitive 
impairment and intellectual disabilities and Alzheimer’s 
disease. Although the different medical aspect of DS is 
well-known, however properties of Alzheimer’s disease in 
subjects with DS has not been well discussed so far.
Methods
Search Strategy
We performed an updated review on relevant research 
relating DS and cognitive function by an electronic 
literature search in the health databases among English 
articles published before 2019. A total of 6 research 
databases, including PubMed, Scopus, EMBSCO, 
CINAHL, ISC, and Cochrane Library were searched 
for this review by using keywords: ‘Down syndrome,” 
“cognitive dysfunction,” “cognitive impairment,” 
Dementia” and “Alzheimer’s disease.” The result included 
40 articles selected based upon their relevance to DS and 
Alzheimer’s disease.
Pathophysiology 
Dementia is common in adults with DS. Recent studies 
indicate that Alzheimer’s disease neuropathological 
changes occur almost in all people with DS after forth 
decades.7 Also, data show that nearly 40% of people with 
DS known as the case of dementia after the 60s.7
Increased risk for developing early-onset Alzheimer’s 
disease is associated with overexpressed on chromosome 
21. Amyloid precursor protein (APP) is an integral 
membrane protein expressed in many tissues and 
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concentrated in the synapses of neurons.8, 9 This protein 
yields the toxic amyloid protein that forms plaques in 
the brain and damages brain cells, and their connections 
coded for chromosome 21. In DS, due to an extra copy 
of chromosome 21, AAP production is 1.5 times as many 
apps as the normal population. These results in the excess 
build-up of the abnormal amyloid breakdown.7
Presentation of dementia is different in DS, and 
symptoms related to frontal lobe deterioration like 
personality and behavior changes are more notable.10, 
11 It should consider that the behavioral and emotional 
changes in DS may occur because of the complexity 
of Alzheimer’s disease diagnosis in people with DS in 
comparison with the normal population.12
Increased prevalence of dementia in older people with 
DS has implications not only for individuals concerned but 
will also demand changes in service provision and impact 
in terms of increased caregiver stress and economic cost.13
Clinical Symptoms
Due to the difficulty of dementia diagnosis in DS, 
the investigator attempts to explain the standardized 
assessment methods. Recently developed instruments 
based on either informant interview or direct cognitive 
assessment.14,15
Possible reasons for delayed diagnosis of Alzheimer’s 
disease in people with DS, including (1) Inherent 
difficulties in diagnosing cognitive decline in those 
with a pre-existing cognitive impairment. (2) Lake 
of appropriate standard screening tools for assessing 
cognitive impairment in this population. (3) Difficulty 
with determining of subtle cognitive decline, particularly 
in people who have not attained many skills and in those 
living in a residential setting with low environmental 
demands.16-18
In the last decades, physicians used their clinical 
judgment and criteria from the International Classification 
of Disease (ICD) and Diagnostic Statistical Manual of 
Mental Disorders-IV text revision (DSM-IV-TR) to 
establish cognitive impairment.19, 20 This judgment was 
most accurate in identifying previously diagnosed cases 
compared with ICD-10 criteria and DSM-IV-TR criteria. 
Over time the DSM-IV has recently been replaced by 
the DSM-5, which introduced a new diagnostic category 
for the mild neurocognitive disorder, which may help to 
make earlier diagnoses in DS.20
Comorbidities 
DS is associated with a wide range of medical conditions 
such as cardiac defects, leukemia, gastrointestinal 
issues, vision and hearing issues, dental issues, thyroid 
disease, obstructive sleep apnoea, epilepsy, and 
Alzheimer’s disease.21 The prevalence of dementia has 
not any correlation with these conditions does not change 
significantly in the presence of dementia, and physicians 
should be aware of their emergence irrespective of 
cognitive decline.8
It has well known that epilepsy occurrence is more 
common in DS in compare than in comparison with the 
general population.22,23 The exact frequency of epilepsy in 
DS is unclear; however, more recent studies have reported 
a prevalence of seizures 1% to 13%.24
Epilepsy is more common in those with DS who 
suffer from dementia. This prevalence is more than 
70% in a group with dementia. On the other hand, 
epilepsy diagnosis is a significant predictor of morbidity 
and mortality in people with DS.25, 26 The incidence of 
cardiovascular events in DS is nearly 25% in comparison 
with controls.27 Haemorrhagic strokes were more common 
in people with DS. This condition is mostly because of 
cerebral amyloid angiopathy due to the deposition of 
amyloid-beta within the walls of cerebral blood vessels, 
which results in intracerebral hemorrhage.28
Diagnosis 
Nowadays, several tests have recently been shown to 
be useless in case of severing intellectual disability or 
dementia. This issue displays the importance of the 
need to develop more specific neurocognitive tools for 
people with DS. However, object memory, semantic 
verbal fluency, the cued recall task, Tower of London, 
the CANTAB paired associate learning and simple 
reaction time tasks and visuomotor precision tasks are 
between the suitable cognitive test for distinguishing 
between those with and without dementia and tracking 
dementia-related decline.8,29-32 Validation of the NIH 
Toolbox (HealthMeasures, Evanston, Illinois, USA) 
Cognitive Battery for intellectual disability found that 
Flanker inhibition/ attention tasks, picture vocabulary, 
oral reading, and picture sequence memory tasks were 
accessible to those with intellectual disability.
In contrast, dimensional change card sort, pattern 
comparison, and list sorting tasks showed large floor 
effects, limiting their suitability as trial outcome 
measures.33 However, this study focused on a young 
sample, including individuals with Fragile X syndrome 
and idiopathic intellectual disability; thus, the suitability 
of these tasks in older adults with DS remains unclear.34 
The Rapid Assessment for Developmental Disabilities 
battery and the NeuroTrax (Mindstreams, Newark, 
NJ, USA) Moderate to Severe Impairment Assessment 
Battery have also proposed as suitable tools for assessing 
cognitive function in those with DS. However, neither 
study reported full performance data.35 A novel informant 
questionnaire addressing executive function, memory, 
and language skills in DS was found to have high 
internal consistency, test-retest reliability, and interrater 
reliability. This questionnaire could reliably discriminate 
between those with and without dementia, but showed 
no significant effects of age or sex, suggesting it could 
be useful for tracking cognitive decline, mainly where 
individuals are unable to engage with standard cognitive 
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assessments.36 
Recent studies showed that behavioral and psychological 
symptoms and executive dysfunction might precede 
memory impairment in DS dementia.3,10,37 Immediate 
memory impairment is one of the earliest signs of 
dementia in people with DS.38 However, more studies are 
necessary to identify the sequence of early changes in DS. 
It should consider that not all cases of cognitive decline in 
DS are the result of dementia.
 Neuroimaging is a useful tool for evaluating 
biomarkers associated with the progression of dementia 
in people with DS. Positron emission tomography scans 
with amyloid-beta-binding compounds showed amyloid 
deposition and its association with dementia in DS. In 
a study by Sabbagh et al, mean standard uptake value 
ratios (SUVRs) assessed as the primary outcome measure 
of fibrillar amyloid-beta burden in individuals with 
DS. Their results showed significant group differences 
in mean SUVRs reported, with uptake higher in DS 
individuals compared with controls, and greater still in 
those with DS and dementia.39, 40 Another study using PET 
demonstrated that standard uptake value ratios binding 
correlated with age, but not with cognitive decline.41 
Annus et al showed Pittsburgh compound B (another 
amyloid beta-binding compound) binding first in the 
striatum around age 40 years that significantly increased 
in several brain regions by age 50 years. They also found 
that PiB binding significantly correlated with diagnostic 
status and history of cognitive decline.42 These studies 
suggest that PET imaging techniques could be useful to 
stage DS in the presymptomatic period based on amyloid 
positive condition on scans and to control the specific 
changes associated with the progression of Alzheimer’s 
disease. Other investigations, such as of EEG biomarkers, 
revealed a correlation between cognitive decline and theta 
slowing.43
Treatment Options
In the case of early diagnosis, effective therapeutic 
intervention such as acetylcholinesterase inhibitors and 
psycho-social supports, including appropriate support for 
carers, can be helpful. 
Acetylcholine esterase inhibitors could be beneficial in 
individuals with DS who have dementia; however, there is 
a lake of enough evidence for its efficacy.44 
Natural DYRK1A inhibitor epigallocatechin-3-gallate 
(EGCG), is useful in Alzheimer’s disease in DS, as 
the DYRK1A gene situated on chromosome 21.45 In a 
randomized placebo-controlled trial on EGCG, after 12 
months, in adults with DS, those in the treatment arm 
had significantly higher scores in measures of visual 
recognition memory, inhibitory control, and adaptive 
behaviour.45 Another randomized placebo-controlled 
trial showed no difference between drug and placebo on 
the primary outcome (a brief praxis test), dementia rates, 
or secondary outcomes in individuals with DS with 1000 
IU of vitamin E orally twice daily for three years.46
 Cooper et al. reported a randomized placebo-controlled 
trial of simvastatin to prevent dementia in people with 
DS. Although the results were meaningful, the trial was 
too small to demonstrate the benefit of the simvastatin.8
Conclusion
The unique presentation of Alzheimer’s disease in 
individuals with DS made these populations as specific 
community unique population for researching and 
developing clinical trials of drugs for primary prevention 
of Alzheimer’s disease. Further work is necessary to 
understand the progression of the disorder and its 
relationship with the development of symptoms during 
the presymptomatic period of Alzheimer’s disease in DS. 
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